Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, demonstrating promising results in reducing blood pressure and albuminuria in chronic kidney disease patients. The company plans to file a New Drug Application with the FDA in late 2025 or early 2026.

Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.

Mineralys Therapeutics presented subgroup analyses from its Phase 3 Launch-HTN trial, demonstrating lorundrostat's efficacy in reducing blood pressure across diverse high-risk patient populations with uncontrolled hypertension, with consistent safety and meaningful clinical results.

Mineralys Therapeutics has priced a public offering of 9,803,921 shares at $25.50 per share, expecting to raise approximately $250 million to fund clinical development and corporate activities.

Mineralys Therapeutics announced positive results from the Phase 3 Launch-HTN trial of its drug lorundrostat for the treatment of uncontrolled or resistant hypertension. The trial demonstrated clinically meaningful and sustained reductions in systolic blood pressure with a favorable safety profile.

Mineralys Therapeutics announced positive results from the Advance-HTN trial, which evaluated the efficacy and safety of their drug lorundrostat in patients with uncontrolled or resistant hypertension. The 50 mg dose of lorundrostat demonstrated a significant reduction in 24-hour ambulatory blood pressure, with a favorable safety profile.

Mineralys Therapeutics has completed enrollment for its pivotal Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company expects to announce topline data in Q1 2025.

Mineralys Therapeutics, Inc. (MLYS) released its Q2 2024 financial results, which missed analyst consensus estimates, causing a sharp drop in the company's stock price. Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Mineralys investors.

Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 million. Compass Minerals International shares fell 9% to $20.52 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Syra Health Corp. (NASDAQ: SYRA) shares jumped 310% to $4.71 after the company announced a partnership for a federal contract valued at $75 billion. Hitek Global Inc. (NASDAQ: HKIT) surged 305% to $4.6220 after jumping more than 60% on Wednesday. MicroAlgo Inc. (NASDAQ: MLGO) shares climbed 160% to $1.48. CCSC Technology International Holdings Limited (NASDAQ: CCTG) shares gained 90.3% to $4.9299 after falling 20% on Wednesday. U Power Limited (NASDAQ: UCAR) climbed 75% to $0.1153. The company appointed Jean Christophe von Pfetten as an independent director and a member of the Board’s Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, effective February 1, 2024. WiMi Hologram Cloud Inc. (NASDAQ: WIMI) shares rose 53.3% to $1.2290 after gaining over 26% on Wednesday. Bit Brother Limited (NASDAQ: BETS) shares climbed 51.2% to $2.69 amid strength in Bitcoin. Arm Holdings plc (NASDAQ: ARM) shares climbed 47.3% to $113.41 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates. Zhongchao Inc. (NASDAQ: ZCMD) rose 41.5% to $0.4250. WeTrade Group, Inc. (NASDAQ: WETG) gained 38.6% to $3.05. Meiwu Technology Company Limited (NASDAQ: WNW) jumped 37% to $1.6205. Healthcare Triangle, Inc. (NASDAQ: HCTI) surged 36% to $3.8250. Oscar Health, Inc. (NYSE: OSCR) shares rose 21.2% to $16.27 after the company reported better-than-expected fourth-quarter financial results. Roma Green Finance Limited (NASDAQ: ROMA) shares gained 20.4% to $0.94 after declining over 5% on Wednesday. Mineralys Therapeutics, Inc. (NASDAQ: MLYS) surged 18.5% to $14.77. Mineralys Therapeutics announced ...

U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday. Shares of Arm Holdings plc (NASDAQ: ARM) shares rose sharply during Thursday’s session after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates. Arm Holdings reported adjusted quarterly earnings of 29 cents per share, which beat the analyst consensus estimate of 25 cents by 16%. The company reported quarterly sales of $824 million, which beat the analyst consensus estimate of $761.62 million by 8.19%. Arm Holdings shares surged 47.3% to $113.41 on Thursday. Here are some other big stocks recording gains in today’s session. Oscar Health, Inc. (NYSE: OSCR) shares gained 21.2% to $16.27 after the company reported better-than-expected fourth-quarter financial results. Mineralys Therapeutics, Inc. (NASDAQ: MLYS) climbed 18.5% to $14.77. Mineralys Therapeutics announced a $120 million private placement financing. Viking Therapeutics, Inc. (NASDAQ: VKTX) gained 17.6% to $28.78 following quarterly results. Bitdeer Technologies Group (NASDAQ: BTDR) rose 17.6% to $8.34. QuinStreet, Inc. (NASDAQ: QNST) gained 15.4% to $14.90 following upbeat results. AST SpaceMobile, Inc. (NASDAQ: ASTS) rose ...